actively trading these days
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Love this upward pressure.
And now, of course, we are in the middle of the summer doldrums. Low volume and little enthusiasm for anything.
Because short-term traders always dominate the pps in the OTC, not investors. But, IMO, investors will eventually win with this one.
Traders are being very cautious this am. Waiting to see how the wind blows.
LiveWire Ergogenics Announces Final Approval to Operate a Commercial Cannabis Business in the County of San Luis Obispo California
BY GlobeNewswire
— 9:00 AM ET 07/06/2021
Anaheim, CA, July 06, 2021 (GLOBE NEWSWIRE) -- LiveWire Ergogenics Inc. ( LVVV ) , a company focused on acquiring, managing, and licensing special purpose real estate properties conducive to produce high-quality, handcrafted, and organically grown cannabis products for medical and recreational adult-use in California, today announced that its affiliate company Estrella River Farms ("ERF") has received its final "Approval to Operate" letter from the County of San Luis Obispo, California. This approval authorizes the operation of a commercial cannabis business as conditioned and licensed on the historic Estrella Ranch in Paso Robles, California.
The "Approval to Operate" letter was the final confirmation required from the County to begin cultivation, and plants can now go in the ground. The official letter is the end of a nearly 2-year difficult journey to navigate the complex and time-consuming County and State legal and environmental compliance process.
Bill Hodson, CEO of LiveWire and Managing Member of ERF states,"Our teams have built an outstanding facility at Estrella Ranch. Their experience, hard work, and dedication was essential in securing the license for the initial acreage of outdoor cannabis cultivation and to bring to life the world's first 'Estate Grown Weedery™.' ERF can now officially begin cultivating the highest quality, organically grown, handcrafted cannabis on a family-style farm in the most beautiful setting in the Central Coast of California, surrounded by hundreds of the finest wineries in the Country."
"The rigorous and costly application and evaluation process took about 20 months to complete, and its successful conclusion is the most significant milestone so far in the execution of our long-term business plan. While we consider this just the beginning of our journey, this final approval will allow us to accelerate the implementation of our business plan on Estrella Ranch. While plants are being prepared to go in the ground as you read this, LiveWire is continuing its responsible strategy to accelerate growth and generate revenue and profits for its shareholders for years to come," concludes Hodson.
I hear ya, and I get it. This is amazing performance for an OTC stock on a Friday before a 3-day weekend.
This is holding up remarkably well on very heavy volume.
Is that the only way this company communicates?
Ah, I did not see that. In fact, I still don't.
Why the surge in volume all of a sudden?
Looks like we go up this am.
Tells us there are about 3.5B shares out there.
If you follow this or any OTC stock hour by hour, you will be disappointed. Follow them month by month. In the case of LVVV, that is a positive.
I've seen that the past couple of days, where the bid is higher than the ask. Means nothing premarket.
This should be an interesting week here.
I see that, and it is a Friday. But I feel lucky today.
I think we close green today.
I agree. I just checked the annual weather for that county, and it never gets below 40 degrees.
For those who might be new here. Info on Conrad Huss.
https://www.marketscreener.com/business-leaders/Conrad-Huss-06DT5B-E/biography/
IMO, this refers to "multiple departments" in SLO, not multiple counties.
We closed up 60% yesterday. Not likely to close green today, but I'll take the consolidation we are seeing.
Probably not yet.
Looks like a probable gap up this am.
And after today, the new base may be .0025. I like this stair-step upward movement.
I would love for us to get to at least .005 BEFORE the big news hits. Then, we move up from there.
At least now we seem to have a solid base at .002. A week ago it was about .0015.
Finally, we broke through that psychological barrier---.002. IMO, we move now.
We just can't seem to break through .002.
How can a company be "delisted" if they are not "listed"?
NEWS!
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract
Topline trial data expected in Q1 2022
BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the administration of the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. Topline results from the trial are expected in the first quarter of 2022.
“Dosing the first patient in the RESERVOIR clinical trial marks a significant milestone for AzurRx and the development of niclosamide as a potential treatment for COVID-19-related GI infections,” said James Sapirstein, Chief Executive Officer of AzurRx BioPharma. “There are currently no approved treatments available for COVID-19-related GI infections. If our development program is successful, we believe that FW-1022 could help prevent reinfection and the spread of COVID-19, as well as treat certain potentially severe complications that many people believe to be caused by the ability of SARS-CoV-2 to hide in reservoirs within the GI tract. We believe our micronized oral niclosamide therapy has the potential to target the virus directly in the gut and play an important role in treating COVID-19 patients experiencing the damaging aftereffects of COVID-19-related GI infection.”
The RESERVOIR clinical trial is designed as a two-part, two-arm, placebo-controlled Phase 2 study. The trial’s primary objectives are to confirm the safety of FW-1022 in the treatment of patients with COVID-19-related GI infections and to evaluate its efficacy in clearing SARS-CoV-2 from the GI tract. The primary efficacy measure of the RESERVOIR trial is the rate of fecal SARS-CoV-2 clearance (rectal swab or stool sample) assessed by RT-PCR, comparing the niclosamide arm to the placebo arm for up to six months. These long-term observation data could indicate that niclosamide treatment has the potential to improve “long haul” COVID-19 symptoms.
“As a practicing clinician, I have treated hundreds of COVID-19 patients with many reporting GI issues resulting from the virus, including severe diarrhea, vomiting and abdominal pain. However, COVID-related GI infection remains an underappreciated and often untreated aspect of the disease despite its prevalence and adverse impact on the patient,” said Salma Saiger, M.D., of SMS Clinical Research, LLC and an investigator with the RESERVOIR clinical trial. “Given this, there is a pressing need to develop therapeutics to directly treat SARS-CoV-2 that may be hiding in the GI tract. Preclinical evidence suggests that micronized niclosamide could provide such an opportunity, and I am excited to be part of the investigative team researching the drug in the Phase 2 RESERVOIR trial.”
“Evidence continues to build in support of niclosamide as a potential COVID-19 therapy, including research from the Institut Pasteur Korea suggesting that niclosamide could be 40 times more potent than remdesivir in inhibiting SARS-CoV-2,” said James Pennington, M.D., Chief Medical Officer of AzurRx. “We believe FW-1022, our micronized formulation of niclosamide, is ideally equipped to clear SARS-CoV-2 hiding in the gut due to its proven safety profile and known effectiveness in treating other GI ailments, and its ability to remain in the gut for long periods of time. We look forward to reporting topline data from RESERVOIR in early 2022.”
More information about this clinical trial is available at ClinicalTrials.gov.
About COVID-19 Gastrointestinal Infections
Gastrointestinal infection symptoms (severe diarrhea, vomiting and abdominal pain) have been reported in approximately 18% of COVID-19 cases.1 Of the 33 million individuals who are reported to have contracted COVID-19 in the U.S.,2 this would translate into 6 million patients having GI infection. Of the 165 million cases globally,3 it would translate into almost 30 million patients. Furthermore, approximately 10% of patients who were infected with COVID have persistent symptoms months after their initial diagnosis.3 Approximately 86% of these COVID “long haulers” are reported to have GI infection symptoms, with 60% continuing to have diarrhea months after their initial infection.4
There is some evidence to support the view that the GI tract is a possible reservoir for recurrence and fecal spread of the COVID-19 virus as ACE-2, the entry receptor for COVID-19, is highly expressed on GI cells. There currently is no targeted treatment for COVID GI infections.
About Niclosamide
Niclosamide is a prescription small molecule drug listed as an essential medicine by the World Health Organization (WHO). Niclosamide has been safely used on millions of patients for other clinical indications. In the U.S., niclosamide was approved by the U.S. Food and Drug Administration (FDA) in 1982 for the treatment of intestinal tapeworm infections. In addition to its antihelminthic activity, niclosamide has demonstrated anti-inflammatory and anti-viral properties.
There remains an urgent need to develop new medicines that can be manufactured at large scale quickly to treat COVID-19. Niclosamide was recently identified by the Institut Pasteur Korea as a potent inhibitor of SARS-CoV-2, the virus causing COVID-19, with potency 40X greater than remdesivir.5 Additionally, emerging evidence confirms the severe GI-related complications of COVID and potential fecal spread of the virus. The Company’s clinical trials may establish that patients treated with an oral and non-systemic niclosamide formulation that delivers high local GI concentrations have decreased viral load and GI-associated symptoms of COVID. Importantly, the manufacturing process for niclosamide can be scaled up to supply large populations quickly.
FW-1022
FW-1022 is a niclosamide based small molecule which the Company’s clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections. FW-1022 is anticipated to be supplied as an oral immediate release tablet. The formulation to be used has been milled (micronized) to allow superior dissolution in the gut fluids. This in turn may allow local niclosamide concentrations to reach anti-viral levels. Thus, FW-1022 has the potential to benefit COVID patients by decreasing viral load in the GI tract, treating infection symptoms and preventing transmission of the virus through fecal spread.
No, OTC stocks almost never do that.
This is trading like it will bust through .002 today.
Shazzam!
This thing is not keeping current with filings just for fun.
Baloney. Try it and see.
That's the daily "short" report for MMs. Means nothing, and they are all even at the end of each day.
You can't short this or any OTC stock.
Extremely bullish to finish the day at the HOD on 12x normal volume.
Fantastic news today! Now, let's light this candle.
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury
BY GlobeNewswire
— 9:15 AM ET 05/12/2021
Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI ) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Drs. Sabhya Rana, Michael Sunshine and David Fuller presented a poster entitled “Low Dose Ampakine Stimulates Diaphragm Activity and Increases Tidal Volume Following Cervical Spinal Cord Injury in Non-anesthetized Freely Behaving Rats” at the Annual Experimental Biology Conference, which was conducted online this year April 27-30.
The Company has been working with Dr. Fuller at the University of Florida who has funding from NIH, to evaluate the use of our AMPAkines for the treatment of compromised motor function in spinal cord injury (“SCI”). In prior studies, the Fuller Laboratory has shown that acute treatment with AMPAkines CX717 and CX1739 can increase inspiratory phrenic motor output in rat models of incomplete cervical spinal cord injury (SCI), when studied under anesthesia in a surgical setting. AMPAkines were observed to increase motor nerve activity under baseline conditions as well when given in conjunction with acute intermittent hypoxia, a treatment known to stimulate synaptic plasticity.
The results presented at the conference were conducted in awake, freely moving rats, a condition analogous to that experienced by SCI patients in the real world. At 4 and 14 days following C2 cervical spinal hemi-section injury, rats were given single, low dose (5 mg/kg) intravenous injections of CX717, CX1739 or vehicle. At 4-days following injury, both AMPAkines increased diaphragm motor nerve activity (EMG) ipsilateral to the injured side during both the baseline breathing and the acute respiratory challenge. At 14-days following injury, both AMPAkines produced sustained increases in ipsilateral diaphragm EMG output and increased output during respiratory challenge.
According to Dr. Fuller, “Cervical SCI results in respiratory compromise which is a leading cause of mortality and morbidity. These animal models of motor nerve function following SCI support proof of concept for a new treatment paradigm using AMPAkines to improve motor functions in patients with SCI.”
Dr. Arnold Lippa, Chief Scientific Officer of the Company said that, “We are continuing our collaborative preclinical research with Dr. Fuller to determine whether other forms of motor activity might be improved. At the same time, we are planning a clinical trial program focused on developing AMPAkines for the restoration of certain motor functions in patients with SCI. The Company is working with researchers at highly regarded clinical sites to finalize a Phase 2 clinical trial protocol, which we intend to submit to the FDA.”
Tim Jones, CEO and President of the Company said that “The ongoing collaboration between RespireRx and the University of Florida has generated potentially groundbreaking data in the treatment of spinal cord injury. We are very excited by the role that our AMPAkine product candidates may play in further progressing much needed treatments for SCI.”
A copy of the poster presented at the Annual Experimental Biology Conference may be viewed on our website at www.respirerx.com/presentations/